Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$8.54
-0.3%
$6.76
$4.80
$18.13
$326.71M1.39571,202 shs817,407 shs
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$35.47
+0.1%
$37.86
$1.72
$54.30
$216.90M1.11359,453 shs10,086 shs
Septerna, Inc. stock logo
SEPN
Septerna
$9.64
+4.9%
$6.78
$4.17
$28.99
$429.54MN/A715,609 shs765,547 shs
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
$0.69
-6.1%
$0.51
$0.33
$0.83
$96.20M0.35122,508 shs78,734 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
0.00%+1.78%+16.46%+22.64%-51.58%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
0.00%-3.93%-17.00%+13.95%+1,027.37%
Septerna, Inc. stock logo
SEPN
Septerna
0.00%-7.82%+42.26%+66.49%+918,999,900.00%
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
0.00%+3.05%+44.47%+31.57%-1.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
3.25 of 5 stars
4.21.00.00.03.53.30.6
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.7824 of 5 stars
3.45.00.00.02.32.50.0
Septerna, Inc. stock logo
SEPN
Septerna
2.4922 of 5 stars
3.40.00.00.04.01.70.6
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
2.7073 of 5 stars
3.55.00.00.02.61.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
2.43
Hold$17.86109.20% Upside
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.75
Moderate Buy$55.3356.00% Upside
Septerna, Inc. stock logo
SEPN
Septerna
2.75
Moderate Buy$27.00180.08% Upside
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
3.00
Buy$1.50116.76% Upside

Current Analyst Ratings Breakdown

Latest XTNT, MNPR, ITOS, and SEPN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Septerna, Inc. stock logo
SEPN
Septerna
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$20.00 ➝ $25.00
5/16/2025
Septerna, Inc. stock logo
SEPN
Septerna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $18.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$16.00 ➝ $13.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$12.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$16.00 ➝ $12.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$47.00 ➝ $9.00
5/13/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$15.00 ➝ $8.00
4/29/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$17.00 ➝ $16.00
4/2/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$35M9.33N/AN/A$16.08 per share0.53
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/A$1.88 per shareN/A
Septerna, Inc. stock logo
SEPN
Septerna
$977K439.65N/AN/AN/A
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
$91.30M1.05$0.03 per share20.06$0.39 per share1.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$112.64M-$3.04N/AN/AN/AN/A-20.11%-17.50%8/14/2025 (Estimated)
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$8.40M-$3.48N/AN/AN/AN/A-107.21%-87.57%8/8/2025 (Estimated)
Septerna, Inc. stock logo
SEPN
Septerna
N/AN/A0.00N/AN/AN/AN/AN/A6/26/2025 (Estimated)
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
$660K-$0.13N/AN/A-15.45%-37.07%-18.47%8/6/2025 (Estimated)

Latest XTNT, MNPR, ITOS, and SEPN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Septerna, Inc. stock logo
SEPN
Septerna
-$0.38-$0.49-$0.11-$0.49N/A$0.22 million
5/13/2025Q1 2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.65-$0.38+$0.27-$0.38N/AN/A
4/28/2025Q1 2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$0.94-$0.80+$0.14-$0.80$9.35 millionN/A
3/31/2025Q4 2024
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.36-$2.23-$1.87-$2.23N/AN/A
3/27/2025Q4 2024
Septerna, Inc. stock logo
SEPN
Septerna
-$0.69-$0.64+$0.05-$0.64$0.13 million$0.21 million
3/5/2025Q4 2024
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$1.14-$1.01+$0.13-$1.01N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/AN/A
Septerna, Inc. stock logo
SEPN
Septerna
N/AN/AN/AN/AN/A
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/A
14.80
14.80
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/A
5.41
5.41
Septerna, Inc. stock logo
SEPN
Septerna
N/AN/AN/A
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
0.42
2.12
0.88

Institutional Ownership

CompanyInstitutional Ownership
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
97.16%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1.83%
Septerna, Inc. stock logo
SEPN
Septerna
N/A
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
69.33%

Insider Ownership

CompanyInsider Ownership
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
12.50%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
20.50%
Septerna, Inc. stock logo
SEPN
Septerna
4.30%
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
9.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
9038.27 million31.97 millionOptionable
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
106.12 million3.97 millionNot Optionable
Septerna, Inc. stock logo
SEPN
Septerna
N/A44.56 millionN/AN/A
Xtant Medical Holdings, Inc. stock logo
XTNT
Xtant Medical
120139.01 million125.52 millionNot Optionable

Recent News About These Companies

Xtant Medical sees Q1 revenue $32.8M-$33.1M, two estimates $30.65M
Xtant Medical price target lowered to $2 from $3 at BTIG

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
iTeos Therapeutics stock logo

iTeos Therapeutics NASDAQ:ITOS

$8.54 -0.02 (-0.28%)
Closing price 03:59 PM Eastern
Extended Trading
$8.53 -0.01 (-0.07%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Monopar Therapeutics stock logo

Monopar Therapeutics NASDAQ:MNPR

$35.47 +0.02 (+0.06%)
Closing price 03:59 PM Eastern
Extended Trading
$35.55 +0.08 (+0.23%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Septerna stock logo

Septerna NASDAQ:SEPN

$9.64 +0.45 (+4.90%)
Closing price 03:59 PM Eastern
Extended Trading
$9.65 +0.01 (+0.16%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

Xtant Medical stock logo

Xtant Medical NYSEAMERICAN:XTNT

$0.69 -0.04 (-6.08%)
Closing price 03:58 PM Eastern
Extended Trading
$0.68 -0.01 (-1.16%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.